Duncker Streett & Co. Inc. Has $1.34 Million Holdings in Medtronic PLC (MDT)
Duncker Streett & Co. Inc. lifted its stake in shares of Medtronic PLC (NYSE:MDT) by 4.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 17,269 shares of the medical technology company’s stock after purchasing an additional 705 shares during the quarter. Duncker Streett & Co. Inc.’s holdings in Medtronic were worth $1,343,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of MDT. Vanguard Group Inc. lifted its holdings in shares of Medtronic by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 104,776,036 shares of the medical technology company’s stock worth $9,298,872,000 after acquiring an additional 2,454,380 shares during the period. BlackRock Inc. raised its holdings in Medtronic by 2.8% in the second quarter. BlackRock Inc. now owns 89,512,229 shares of the medical technology company’s stock valued at $7,944,210,000 after buying an additional 2,476,853 shares during the period. Massachusetts Financial Services Co. MA grew its position in Medtronic by 3.0% in the first quarter. Massachusetts Financial Services Co. MA now owns 58,646,070 shares of the medical technology company’s stock valued at $4,724,526,000 after acquiring an additional 1,729,715 shares in the last quarter. Lazard Asset Management LLC grew its position in Medtronic by 43.8% in the second quarter. Lazard Asset Management LLC now owns 19,669,866 shares of the medical technology company’s stock valued at $1,745,699,000 after acquiring an additional 5,991,094 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Medtronic by 7.3% in the first quarter. Geode Capital Management LLC now owns 13,308,812 shares of the medical technology company’s stock valued at $1,070,622,000 after acquiring an additional 906,581 shares in the last quarter. 81.85% of the stock is currently owned by institutional investors and hedge funds.
A number of research firms have commented on MDT. BidaskClub raised shares of Medtronic from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Royal Bank Of Canada restated a “buy” rating and set a $90.00 price objective on shares of Medtronic in a research note on Monday, August 21st. Oppenheimer restated a “buy” rating and set a $92.00 price objective on shares of Medtronic in a research note on Tuesday, August 22nd. Cowen set a $95.00 target price on Medtronic and gave the stock a “buy” rating in a report on Tuesday, August 22nd. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $92.00 target price (down from $94.00) on shares of Medtronic in a report on Wednesday, August 23rd. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and thirteen have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $88.02.
Shares of Medtronic PLC (NYSE:MDT) traded up $1.05 during mid-day trading on Wednesday, hitting $80.92. The stock had a trading volume of 5,392,200 shares, compared to its average volume of 4,959,266. Medtronic PLC has a one year low of $69.35 and a one year high of $89.72. The firm has a market capitalization of $108,103.88, a price-to-earnings ratio of 17.21, a PEG ratio of 2.20 and a beta of 1.00. The company has a current ratio of 2.40, a quick ratio of 2.05 and a debt-to-equity ratio of 0.50.
Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, November 21st. The medical technology company reported $1.07 EPS for the quarter, topping analysts’ consensus estimates of $0.99 by $0.08. Medtronic had a return on equity of 12.63% and a net margin of 16.93%. The company had revenue of $7.05 billion during the quarter, compared to analyst estimates of $7.05 billion. During the same period in the previous year, the company earned $1.12 earnings per share. The company’s quarterly revenue was down 4.0% compared to the same quarter last year. equities analysts expect that Medtronic PLC will post 4.77 EPS for the current fiscal year.
In other news, CEO Omar Ishrak sold 140,407 shares of the business’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $81.63, for a total transaction of $11,461,423.41. Following the sale, the chief executive officer now directly owns 668,503 shares in the company, valued at $54,569,899.89. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Bryan C. Hanson sold 16,000 shares of the business’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $79.02, for a total value of $1,264,320.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 172,407 shares of company stock valued at $13,974,223. Corporate insiders own 0.31% of the company’s stock.
Medtronic Company Profile
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.